Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Sentinel Lymph Node Staging in Early-Stage Cervical Cancer: A Comprehensive Review

Version 1 : Received: 11 October 2023 / Approved: 12 October 2023 / Online: 12 October 2023 (15:39:39 CEST)

A peer-reviewed article of this Preprint also exists.

Margioula-Siarkou, C.; Almperis, A.; Gullo, G.; Almperi, E.-A.; Margioula-Siarkou, G.; Nixarlidou, E.; Mponiou, K.; Papakotoulas, P.; Sardeli, C.; Guyon, F.; Dinas, K.; Petousis, S. Sentinel Lymph Node Staging in Early-Stage Cervical Cancer: A Comprehensive Review. J. Clin. Med. 2024, 13, 27. Margioula-Siarkou, C.; Almperis, A.; Gullo, G.; Almperi, E.-A.; Margioula-Siarkou, G.; Nixarlidou, E.; Mponiou, K.; Papakotoulas, P.; Sardeli, C.; Guyon, F.; Dinas, K.; Petousis, S. Sentinel Lymph Node Staging in Early-Stage Cervical Cancer: A Comprehensive Review. J. Clin. Med. 2024, 13, 27.

Abstract

Cervical cancer (CC) continues to be a significant global public health concern, even with preventive measures in place. In women with early-stage CC, the status of lymph nodes is of paramount importance, not only for final prognosis but also for determining the best therapeutic strategy. According to main international guidelines, pelvic full lymphadenectomy (PLND) is recommended for lymph node staging. However, in these early stages of CC, Sentinel lymph node biopsy (SLNB) has emerged as a precise technique for evaluating lymph node involvement, improving its morbidity profile. We performed a literature review through PubMed articles about progress on the application of SLNB in women with early-stage CC focusing on the comparison with PET/CT and PLND in terms of oncological outcomes and diagnostic accuracy. While the superiority of SLNB is clear compared to radiologic modalities, it demonstrates no clear oncologic inferiority over PLND, given the higher detection rate of positive lymph nodes and predominance of no lymph node recurrences. However, due to a lack of prospective evidence, particularly concerning long-term oncological safety, SLNB is not the current gold standard. With careful patient selection and adherence to straightforward protocols, a low false negative rate can be ensured. The aim of the ongoing prospective trials is to address these issues.

Keywords

Lymph Nodes; Lymphadenectomy; Diagnostic Imaging; Survival Analysis

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.